Cargando…

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report

INTRODUCTION: Animal studies have reported that treatment with angiotensin II receptor blockers reduced kidney sodium-dependent glucose cotransporter expression. We therefore hypothesized that patients with hypertension treated with an angiotensin II receptor blocker (candesartan) would probably hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Shuichi, Shibusawa, Ryo, Tagaya, Yuko, Saito, Tsugumichi, Yamada, Eijiro, Shimoda, Yoko, Satoh, Tetsurou, Okada, Junichi, Yamada, Masanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302117/
https://www.ncbi.nlm.nih.gov/pubmed/25515334
http://dx.doi.org/10.1186/1752-1947-8-428
_version_ 1782353740629540864
author Okada, Shuichi
Shibusawa, Ryo
Tagaya, Yuko
Saito, Tsugumichi
Yamada, Eijiro
Shimoda, Yoko
Satoh, Tetsurou
Okada, Junichi
Yamada, Masanobu
author_facet Okada, Shuichi
Shibusawa, Ryo
Tagaya, Yuko
Saito, Tsugumichi
Yamada, Eijiro
Shimoda, Yoko
Satoh, Tetsurou
Okada, Junichi
Yamada, Masanobu
author_sort Okada, Shuichi
collection PubMed
description INTRODUCTION: Animal studies have reported that treatment with angiotensin II receptor blockers reduced kidney sodium-dependent glucose cotransporter expression. We therefore hypothesized that patients with hypertension treated with an angiotensin II receptor blocker (candesartan) would probably have an increased response to sodium-dependent glucose cotransporter inhibitor therapy (ipragliflozin) compared with patients treated with alternative hypertensive medications such as calcium channel blockers (nifedipine). Although sodium-dependent glucose cotransporter inhibitor (ipragliflozin) is a new anti-diabetic medicine, the clinical efficacy in the Japanese population has not been fully evaluated. We compared the combined effect of angiotensin II receptor blocker candesartan plus ipragliflozin with nifedipine plus ipragliflozin therapy and found that the combination of candesartan plus ipragliflozin was more effective in increasing glycosuria and lowering plasma glucose. CASE PRESENTATION: A 57-year-old Japanese man with essential hypertension was treated with candesartan. Candesartan was switched to nifedipine for the initial 10 days of an observation period and 5 days later he was started on ipragliflozin (day 6 of nifedipine treatment) with nifedipine for the next 5 days. Thereafter (from day 11 to day 20), candesartan was started instead of nifedipine and ipragliflozin was continued. In the last 5 days ipragliflozin was stopped and he was treated with candesartan alone. Neither nifedipine alone (0.038+/-0.004) nor candesartan alone (0.048+/-0.006) produce any trace amount of glycosuria. However, the extent of glycosuria under ipragliflozin with candesartan treatment (37.5+/-8.45) was significantly greater than that of ipragliflozin with nifedipine (23.75+/-0.35; P<0.05). CONCLUSION: Candesartan demonstrated additive actions with ipragliflozin to increase glycosuria compared to ipragliflozin with nifedipine treatment.
format Online
Article
Text
id pubmed-4302117
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43021172015-01-23 Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report Okada, Shuichi Shibusawa, Ryo Tagaya, Yuko Saito, Tsugumichi Yamada, Eijiro Shimoda, Yoko Satoh, Tetsurou Okada, Junichi Yamada, Masanobu J Med Case Rep Case Report INTRODUCTION: Animal studies have reported that treatment with angiotensin II receptor blockers reduced kidney sodium-dependent glucose cotransporter expression. We therefore hypothesized that patients with hypertension treated with an angiotensin II receptor blocker (candesartan) would probably have an increased response to sodium-dependent glucose cotransporter inhibitor therapy (ipragliflozin) compared with patients treated with alternative hypertensive medications such as calcium channel blockers (nifedipine). Although sodium-dependent glucose cotransporter inhibitor (ipragliflozin) is a new anti-diabetic medicine, the clinical efficacy in the Japanese population has not been fully evaluated. We compared the combined effect of angiotensin II receptor blocker candesartan plus ipragliflozin with nifedipine plus ipragliflozin therapy and found that the combination of candesartan plus ipragliflozin was more effective in increasing glycosuria and lowering plasma glucose. CASE PRESENTATION: A 57-year-old Japanese man with essential hypertension was treated with candesartan. Candesartan was switched to nifedipine for the initial 10 days of an observation period and 5 days later he was started on ipragliflozin (day 6 of nifedipine treatment) with nifedipine for the next 5 days. Thereafter (from day 11 to day 20), candesartan was started instead of nifedipine and ipragliflozin was continued. In the last 5 days ipragliflozin was stopped and he was treated with candesartan alone. Neither nifedipine alone (0.038+/-0.004) nor candesartan alone (0.048+/-0.006) produce any trace amount of glycosuria. However, the extent of glycosuria under ipragliflozin with candesartan treatment (37.5+/-8.45) was significantly greater than that of ipragliflozin with nifedipine (23.75+/-0.35; P<0.05). CONCLUSION: Candesartan demonstrated additive actions with ipragliflozin to increase glycosuria compared to ipragliflozin with nifedipine treatment. BioMed Central 2014-12-16 /pmc/articles/PMC4302117/ /pubmed/25515334 http://dx.doi.org/10.1186/1752-1947-8-428 Text en © Okada et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Okada, Shuichi
Shibusawa, Ryo
Tagaya, Yuko
Saito, Tsugumichi
Yamada, Eijiro
Shimoda, Yoko
Satoh, Tetsurou
Okada, Junichi
Yamada, Masanobu
Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title_full Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title_fullStr Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title_full_unstemmed Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title_short Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
title_sort glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302117/
https://www.ncbi.nlm.nih.gov/pubmed/25515334
http://dx.doi.org/10.1186/1752-1947-8-428
work_keys_str_mv AT okadashuichi glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT shibusawaryo glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT tagayayuko glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT saitotsugumichi glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT yamadaeijiro glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT shimodayoko glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT satohtetsurou glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT okadajunichi glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport
AT yamadamasanobu glycosuriamedicatedwithipragliflozinandnifedipineoripragliflozinandcandesartanacasereport